The 8-bromobaicalein inhibited the replication of dengue, and Zika viruses and targeted the dengue polymerase
Issued Date
2023-12-01
Resource Type
eISSN
20452322
Scopus ID
2-s2.0-85150991033
Pubmed ID
36966240
Journal Title
Scientific Reports
Volume
13
Issue
1
Rights Holder(s)
SCOPUS
Bibliographic Citation
Scientific Reports Vol.13 No.1 (2023)
Suggested Citation
Boonyasuppayakorn S., Saelee T., Huynh T.N.T., Hairani R., Hengphasatporn K., Loeanurit N., Cao V., Vibulakhaophan V., Siripitakpong P., Kaur P., Chu J.J.H., Tunghirun C., Choksupmanee O., Chimnaronk S., Shigeta Y., Rungrotmongkol T., Chavasiri W. The 8-bromobaicalein inhibited the replication of dengue, and Zika viruses and targeted the dengue polymerase. Scientific Reports Vol.13 No.1 (2023). doi:10.1038/s41598-023-32049-x Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/82797
Title
The 8-bromobaicalein inhibited the replication of dengue, and Zika viruses and targeted the dengue polymerase
Other Contributor(s)
Abstract
Dengue and Zika viruses are mosquito-borne flaviviruses burdening millions every year with hemorrhagic fever and neurological symptoms. Baicalein was previously reported as a potential anti-flaviviral candidate and halogenation of flavones and flavanones potentiated their antiviral efficacies. Here, we reported that a chemically modified 8-bromobaicalein effectively inhibited all dengue serotypes and Zika viruses at 0.66–0.88 micromolar in cell-based system. The compound bound to dengue serotype 2 conserved pocket and inhibited the dengue RdRp activity with 6.93 fold more than the original baicalein. Moreover, the compound was mildly toxic against infant and adult C57BL/6 mice despite administering continuously for 7 days. Therefore, the 8-bromobaicalein should be investigated further in pharmacokinetics and efficacy in an animal model.